GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Fusen Pharmaceutical Co Ltd (HKSE:01652) » Definitions » EV-to-EBIT

Fusen Pharmaceutical Co (HKSE:01652) EV-to-EBIT : -66.51 (As of May. 27, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Fusen Pharmaceutical Co EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Fusen Pharmaceutical Co's Enterprise Value is HK$1,226.9 Mil. Fusen Pharmaceutical Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-18.4 Mil. Therefore, Fusen Pharmaceutical Co's EV-to-EBIT for today is -66.51.

The historical rank and industry rank for Fusen Pharmaceutical Co's EV-to-EBIT or its related term are showing as below:

HKSE:01652' s EV-to-EBIT Range Over the Past 10 Years
Min: -74.93   Med: 18.87   Max: 63.79
Current: -66.51

During the past 9 years, the highest EV-to-EBIT of Fusen Pharmaceutical Co was 63.79. The lowest was -74.93. And the median was 18.87.

HKSE:01652's EV-to-EBIT is ranked worse than
100% of 668 companies
in the Drug Manufacturers industry
Industry Median: 17.155 vs HKSE:01652: -66.51

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Fusen Pharmaceutical Co's Enterprise Value for the quarter that ended in Dec. 2023 was HK$1,357.6 Mil. Fusen Pharmaceutical Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-18.4 Mil. Fusen Pharmaceutical Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -1.36%.


Fusen Pharmaceutical Co EV-to-EBIT Historical Data

The historical data trend for Fusen Pharmaceutical Co's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fusen Pharmaceutical Co EV-to-EBIT Chart

Fusen Pharmaceutical Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only 45.72 32.21 29.26 -57.50 -73.59

Fusen Pharmaceutical Co Semi-Annual Data
Dec15 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 29.26 - -57.50 - -73.59

Competitive Comparison of Fusen Pharmaceutical Co's EV-to-EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Fusen Pharmaceutical Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fusen Pharmaceutical Co's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Fusen Pharmaceutical Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Fusen Pharmaceutical Co's EV-to-EBIT falls into.



Fusen Pharmaceutical Co EV-to-EBIT Calculation

Fusen Pharmaceutical Co's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=1226.932/-18.447
=-66.51

Fusen Pharmaceutical Co's current Enterprise Value is HK$1,226.9 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Fusen Pharmaceutical Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-18.4 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Fusen Pharmaceutical Co  (HKSE:01652) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Fusen Pharmaceutical Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 ) =EBIT / Enterprise Value (Q: Dec. 2023 )
=-18.447/1357.55395
=-1.36 %

Fusen Pharmaceutical Co's Enterprise Value for the quarter that ended in Dec. 2023 was HK$1,357.6 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Fusen Pharmaceutical Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-18.4 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Fusen Pharmaceutical Co EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Fusen Pharmaceutical Co's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Fusen Pharmaceutical Co (HKSE:01652) Business Description

Traded in Other Exchanges
N/A
Address
Urban Industrial Zone, Henan Province, Xichuan County, Zhengzhou, CHN
Fusen Pharmaceutical Co Ltd is engaged in manufacturing shuanghuanglian based cold medicine. The product portfolio company includes shuanghuanglian based cold medicine and which includes oral solutions and shuanghuanglian injections, other PCM and western medicine products which include compound ferrous sulphate granules and flunarizine hydrochloride capsules.
Executives
Cao Changcheng 2201 Interest of corporation controlled by you
Quan Xiufeng 2202 Interest of your spouse
Full Bliss Holdings Limited 2101 Beneficial owner
One Victory Investments Limited 2101 Beneficial owner
Cao Zhiming 2201 Interest of corporation controlled by you
Zhou Peilin 2202 Interest of your spouse
Rayford Global Limited 2306 Nominee for another person
Tct (bvi) Limited 2501 Other
The Core Trust Company Limited 2301 Trustee
First Joint Elegant Limited 2101 Beneficial owner
Fung Wai Sze 2202 Interest of your spouse
Lam Yiu Por 2201 Interest of corporation controlled by you

Fusen Pharmaceutical Co (HKSE:01652) Headlines

No Headlines